Stolinsky D C, Jacobs E M, Irwin L E, Pajak T F, Bateman J R
Oncology. 1976;33(4):151-3. doi: 10.1159/000225131.
Trimethylcolchicinic acid methyl ether d-tartrate (TMCA; NSC-36351) was administered daily by mouth to 71 patients with malignant lymphomas. Partical (greater than 50%) responses were observed in eleven of 37 patients with Hodgkin's disesse, two of 22 patients with lymphocytic lymphoma, and one of two patients with mixed cell lymphoma. One complete and three partial responses were noted in nine patients with histiocytic lymphoma. Responses lasted from one to 91+ months (median: four months) and occurred in patients whose disease was resistant to alkylating agents, vinblastine, vincristine, procarbazine, prednisone or BCNU. Toxic effects included leukopenia, thrombocytopenia, nausea, diarrhea, stomatitis, alopecia and dermatitis.
每天口服三甲基秋水仙碱酸甲酯d -酒石酸盐（TMCA；NSC - 36351）对71例恶性淋巴瘤患者进行治疗。在37例霍奇金病患者中有11例出现部分（大于50%）缓解，22例淋巴细胞性淋巴瘤患者中有2例缓解，2例混合细胞淋巴瘤患者中有1例缓解。9例组织细胞性淋巴瘤患者中有1例完全缓解和3例部分缓解。缓解持续时间为1至91 +个月（中位数：4个月），且发生在对烷化剂、长春花碱、长春新碱、丙卡巴肼、泼尼松或卡氮芥耐药的患者中。毒性作用包括白细胞减少、血小板减少、恶心、腹泻、口腔炎、脱发和皮炎。
